Please login to the form below

Not currently logged in


This page shows the latest Volibris news and features for those working in and with pharma, biotech and healthcare.

GSK earns expanded approval for Volibris in Europe

GSK earns expanded approval for Volibris in Europe

Additional indication given to pulmonary arterial hypertension drug. GlaxoSmithKline's pulmonary arterial hypertension drug Volibris has won expanded approval from the European Commission. . ... The expanded authorisation for Volibris will make an

Latest news

  • CHMP October meeting gives recommendations for Pfizer and MSD CHMP October meeting gives recommendations for Pfizer and MSD

    Pfizer's Volibris (ambrisentan) was backed for the treatment of pulmonary arterial hypertension (PAH) with efficacy being shown in idiopathic PAH and PAH associated with connective tissue disease.

  • Gilead and GSK pulmonary hypertension drugs work in tandem Gilead and GSK pulmonary hypertension drugs work in tandem

    Ambrisentan is commercialised by Gilead in the US as Letairis and by GSK outside the US as Volibris, while tadalafil is promoted by GSK in Europe for PAH as Adcirca, under

  • EC green lights Volibris

    GlaxoSmithKline has revealed that the European Commission has granted marketing authorisation for Volibris, which can now be prescribed across the EU market. ... Volibris (ambrisentan) has been developed to treat patients with pulmonary arterial

  • GSK Prepandrix given positive review by EMEA

    GSK also had another of its candidate drugs, Volibris, endorsed by CHMP and the EMEA, and expects final approval and marketing authorisation to be granted by the end of April 2008. ... Eddie Gray, president of Pharmaceuticals Europe for GSK, said: "This

More from news
Approximately 1 fully matching, plus 4 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
Fishawack Group of Companies

The Fishawack Group of Companies is one of the largest independent medical communications and medical marketing specialists, with teams in...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...